EGFR and non-small cell lung carcinoma: The reasons were as follows: (1) both of them belonged to small molecule EGFR-TKIs, aiming at blocking the EGFR signal pathway and inhibiting tumor growth; (2) they were all recommended in the first-line treatment of advanced NSCLC harboring EGFR mutations; (3) few published articles focused on the effect of third-generation TKIs as adjuvant treatment and the excellent outcome generated from ADAURA trial made us produce the data synthesis in one single analysis.